Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Richard Sloan from the University of Michigan was first to document what is referred to as the "accrual anomaly". His 1996 paper found that shares of companies with small or negative accruals vastly outperform (+10%) those of companies with large ones.
BioPharma Credit's Sloan Ratio for the quarter that ended in Dec. 2025 was -3.31%.
As of Dec. 2025, BioPharma Credit has a Sloan Ratio of -3.31%, indicating the company is in the safe zone and there is no funny business with accruals.
BioPharma Credit (LSE:BPCR) Sloan Ratio % Explanation
A former University of Michigan researcher, Richard Sloan's 1996 paper found that shares of companies with small or negative accruals vastly outperform (+10%) those of companies with large ones. In fact, for the 40-year period between 1962 and 2001, buying the lowest accrual companies and shorting the highest accrual companies resulted in an average annual compounded return of 18%, more than double the S&P 500's 7.4% annual return over the same period.
If the Sloan Ratio is between -10% and 10%, the company is in the safe zone and there is no funny business with accruals.
If the Sloan Ratio is less than between -25% and -10% on the negative side, and between 10% and 25% on the positive side, this is a warning stage of accrual build up.
If the Sloan Ratio is less than -25% or greater than 25%, and this ratio is consistent over several quarters or even years, be careful. Earnings are highly likely to be made up of accruals.
As of Dec. 2025, BioPharma Credit has a Sloan Ratio of -3.31%, indicating the company is in the safe zone and there is no funny business with accruals.
BioPharma Credit Sloan Ratio % Related Terms
BioPharma Credit Sloan Ratio % Historical Data
* Premium members only.
The historical data trend for BioPharma Credit's Sloan Ratio % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
LSE:BPCR vs BLK, BX, KKR: Sloan Ratio % Comparison
For the Asset Management subindustry, BioPharma Credit's Sloan Ratio %, along with its competitors' market caps and Sloan Ratio % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
BioPharma Credit Sloan Ratio % vs Asset Management Industry
For the Asset Management industry and Financial Services sector, BioPharma Credit's Sloan Ratio % distribution charts can be found below:
* The bar in red indicates where BioPharma Credit's Sloan Ratio % falls into.
Earnings contain a lot of non cash earnings which is called accruals. The Sloan ratio is a way to identify firms with low non-cash or accrual-derived earnings relative to their cash flow.
BioPharma Credit's Sloan Ratio for the fiscal year that ended in Dec. 2025 is calculated as
For company reported semi-annually, GuruFocus uses latest two semi-annual data as the TTM data.
BioPharma Credit's Net Income for the trailing twelve months (TTM) ended in Dec. 2025 was 72.783 (Jun. 2025 ) + 57.104 (Dec. 2025 ) = $129.9 Mil.
BioPharma Credit's Cash Flow from Operations for the trailing twelve months (TTM) ended in Dec. 2025 was 33.756 (Jun. 2025 ) + 57.339 (Dec. 2025 ) = $91.1 Mil.
BioPharma Credit's Cash Flow from Investing for the trailing twelve months (TTM) ended in Dec. 2025 was 70 (Jun. 2025 ) + 7.484 (Dec. 2025 ) = $77.5 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BioPharma Credit (LSE:BPCR) has a Sloan Ratio % of -3.31% as of Dec. 2025. Sloan ratio measures earnings quality based on the amount of accruals. View historical data on BioPharma Credit and its competitors.
Is BioPharma Credit's Sloan Ratio % too high?
BioPharma Credit's current Sloan Ratio % is -3.31%. Overall, BioPharma Credit has a GF Score™ of 50/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does BioPharma Credit's Sloan Ratio % compare to BLK and BX?
BioPharma Credit's Sloan Ratio % of -3.31% can be compared against companies in the Asset Management industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Sloan Ratio % for an Asset Management company?
A good Sloan Ratio % depends on the Asset Management industry context. However, Sloan Ratio % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Sloan Ratio % mean?
A high Sloan Ratio % can signal that a stock is expensive relative to its fundamentals. Sloan ratio measures earnings quality based on the amount of accruals. View historical data on BioPharma Credit and its competitors. BioPharma Credit's current Sloan Ratio % is -3.31%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BioPharma Credit stock overvalued right now?
Based on GuruFocus' analysis, BioPharma Credit (LSE:BPCR) is currently considered Fairly Valued. The stock's GF Value™ is $0.96, compared to a current price of $0.97 — trading 0.8% above its estimated fair value. The current Sloan Ratio % is -3.31%. BioPharma Credit's overall GF Score™ is 50/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Sloan Ratio % calculated?
Sloan Ratio % is calculated from a company's financial statements. For BioPharma Credit (LSE:BPCR), the current Sloan Ratio % is -3.31% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is BioPharma Credit (LSE:BPCR) Overvalued in 2026?
Based on GuruFocus' analysis, BioPharma Credit stock appears to be overvalued.
The current stock price of $0.97 is trading 0.8% above its estimated GF Value™ of $0.96.
GuruFocus considers BioPharma Credit to be Fairly Valued.
Key valuation signals for LSE:BPCR:
Sloan Ratio %: -3.31%
GF Value™: $0.96 vs. price of $0.97 (0.8% above fair value)
No single metric tells the full story. See the LSE:BPCR stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
BioPharma Credit PLC is an investment trust. Its investment objective is to generate long-term shareholder returns predominantly in the form of sustainable income distributions from exposure to the life sciences industry. The trust focuses on achieving its investment objective through direct or indirect exposure to debt assets, which include royalty investments, senior secured debt, unsecured debt, and credit linked notes. Its diversified investment portfolio is mainly secured by approved life sciences products and the cash flows derived from their sales.
50GF Score
Get the complete analysis for LSE:BPCR
Sloan Ratio % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LSE:BPCR has been successfully added to your 
